Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.

Next Previous
Trial Profile

A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avdoralimab (Primary) ; Ezurpimtrostat (Primary) ; Monalizumab (Primary) ; Nivolumab (Primary) ; Tocilizumab (Primary)
  • Indications COVID 2019 infections; Haematological malignancies; Pneumonia; Solid tumours
  • Focus Therapeutic Use
  • Acronyms IMMUNONCOVID; IMMUNONCOVID-20

Most Recent Events

  • 29 Sep 2022 Status changed from active, no longer recruiting to completed.
  • 04 Aug 2021 Planned End Date changed from 1 Aug 2021 to 1 Dec 2021.
  • 04 Aug 2021 Status changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top